News Breaks |
|
|
| September 28, 2012 |
| 06:01 EDT |  | ACTG, BSX | Acacia Research unit enters into settlement agreement with Boston Scientific
Acacia Research Corporation (ACTG) announced that its Body Science LLC subsidiary has entered into a settlement agreement with Boston Scientific Corporation (BSX). The agreement resolves litigation that was pending in the United States District Court for the District of Minnesota. |
|
|
News For ACTG;BSX From The Last 14 Days Check below for free stories on ACTG;BSX the last two weeks. |
|
|
| May 21, 2013 |
| 05:48 EDT | | BSX | OrbusNeich seizes Boston Scientific stents as part of patent infringement case
 Subscribe for More Information |
|
| May 20, 2013 |
| 09:41 EDT | | BSX | Supreme Court agrees to hear Medtronic-Boston Scientific patent case
Reported by SCOTUSblog live blog of court orders and opinions. |
|
| 06:14 EDT | | ACTG | Acacia Research subsidiary enters into license and settlement agreement with MBO
Subscribe for More Information |
|
| 06:03 EDT | | ACTG | Acacia Research enters into license, settlement agreement with MBO Data, LLC
Subscribe for More Information |
|
| 06:02 EDT | | ACTG | Acacia Research enters into license, settlement agreement with Nextgen Internet
Subscribe for More Information |
|
| May 17, 2013 |
| 06:00 EDT | | ACTG | Acacia Research enters into license, settlement agreement with Mitel Networks
Subscribe for More Information |
|
| May 16, 2013 |
| 16:13 EDT | | BSX | Vascular Solutions files patent infringement complaint against Boston Scientific
Vascular Solutions (VASC) announced that it has filed a patent infringement complaint in the U.S. District Court for the District of Minnesota against Boston Scientific Corporation (BSX). The complaint alleges that Boston Scientific has infringed three patents owned by Vascular Solutions concerning rapid exchange guide extension technology by manufacturing and selling its Guidezilla guide extension catheter which received 510(k) clearance in March. Vascular Solutions is seeking an injunction against Boston Scientific prohibiting the manufacture and sale of its Guidezilla catheter as well as damages for lost profits and legal costs. |
|
| 07:51 EDT |  | BSX | Boston Scientific price target raised to $12 from $9 at JMP Securities
JMP Securities increased its price target on Boston Scientific as the firm believes after speaking with experts that S-ICD devices can be used in 50% of de novo implant cases, up from its previous estimate of 30%. The firm's FY13 and FY14 earnings estimates for the company are well above consensus levels and it reiterates an Outperform rating on the shares. |
|
| 07:28 EDT |  | BSX | I/O Central to host a conference
Subscribe for More Information |
|
| May 14, 2013 |
| 15:33 EDT | | BSX | Boston Scientific has a conference call hosted by JPMorgan
JPMorgan Analyst Weinstein will host a conference call with CEO Mike Mahoney on May 17 at 11 am. |
| |
| 06:02 EDT | | ACTG | Acacia Research subsidiary enters into agreement with BAIS
Acacia Research announced that its Brandywine Communications Technologies subsidiary has entered into a license and settlement agreement with BAIS, dba Bay Area Internet Solutions. This agreement resolves patent litigation that was pending in the United States District Court for the Central District of California. |
|
| May 10, 2013 |
| 10:00 EDT |  | BSX | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 09:03 EDT | | BSX | Boston Scientific receives CEO Mark approval for Rhythmia mapping system
Subscribe for More Information |
|
| 05:46 EDT | | BSX | Boston Scientific upgraded to Outperform from Market Perform at Wells Fargo
Subscribe for More Information |
|
| May 9, 2013 |
| 12:04 EDT | | BSX | Boston Scientific says data show Watchman device superior to warfarin
Boston Scientific reports that the four-year follow-up data from the PROTECT AF clinical trial demonstrated the WATCHMAN Left Atrial Appendage Closure device was statistically superior to warfarin for preventing cardiovascular death, all-cause stroke and systemic embolization. The data demonstrated significant reductions in both cardiovascular and all death compared to warfarin. The data were presented today as a late-breaking clinical trial at Heart Rhythm 2013, the Heart Rhythm Society's 34th Annual Scientific Sessions. |
|
| 09:27 EDT | | BSX | Leerink's medical devices analyst holds a conference call
Subscribe for More Information |
|
| 06:02 EDT | | ACTG | Acacia Research subsidiary enters into license agreement with Office Depot
Subscribe for More Information |
|
| 06:00 EDT | | ACTG | Acacia Research subsidiary enters into settlement agreement with Shutterfly
Subscribe for More Information |
|
| May 8, 2013 |
| 07:38 EDT | | BSX | BofA/Merrill's medical tech analyst hold an analyst/industry conference call
Subscribe for More Information |
|
| May 7, 2013 |
| 06:10 EDT | | ACTG | Acacia Research subsidiary enters into license settlement agreement
Acacia Research announced that its Unified Messaging Solutions subsidiary has entered into a license and settlement agreement with Capital One Financial Corporation and Ing Direct. This agreement resolves patent litigation that was pending in the U.S. District Court for the Western District of Texas. |
| |
|
|
|
|
